Cagrilintide for Obesity

(RENEW 4 Trial)

This trial tests a new medicine called cagrilintide to determine its effectiveness in weight loss. Participants will receive either cagrilintide or a placebo (a treatment with no active medicine) through random assignment. The study spans about 9 months, with participants receiving weekly injections for 26 weeks. Suitable candidates have a BMI over 30, or over 27 with conditions such as high blood pressure, high cholesterol, sleep apnea, or heart disease. As a Phase 3 trial, this study represents the final step before FDA approval, allowing participants to contribute to the potential availability of a new weight-loss treatment.

Research has shown that cagrilintide has been tested in people and is generally safe and well-tolerated. Some side effects, such as nausea, vomiting, diarrhea, and injection site reactions, have been reported. These side effects are usually mild, while more serious side effects occur less frequently. Previous studies found that cagrilintide's safety profile is similar to other treatments in its group, like incretin and amylin-based therapies. This suggests that most people can use the treatment without major problems.¹²³⁴⁵

Unlike the standard obesity treatments that often focus on appetite suppression alone, Cagrilintide offers a novel approach by acting on the amylin receptor, which plays a crucial role in regulating appetite and energy balance. This mechanism is different from typical treatments like GLP-1 agonists, which target the GLP-1 receptor to manage weight. Researchers are excited about Cagrilintide because it not only targets a different receptor but also has the potential to be more effective when used in combination with other treatments. This dual approach could lead to more significant weight loss and improved outcomes for individuals struggling with obesity.

Research has shown that cagrilintide is promising for weight loss. In one study, participants taking cagrilintide lost an average of 11.8% of their body weight, while those on a placebo lost only 2.3% over 68 weeks. Another study found that cagrilintide led to significant weight loss and was well-tolerated. All doses of cagrilintide resulted in more weight loss than a placebo, with higher doses proving especially effective. These findings suggest that cagrilintide could be a strong option for managing obesity. Participants in this trial will receive cagrilintide in different configurations, with some receiving placebo treatments for comparison.⁶⁷⁸⁹¹⁰